Harnessing the therapeutic potential of mesenchymal stem cell-derived exosomes in cardiac arrest: Current advances and future perspectives

Biomed Pharmacother. 2023 Sep:165:115201. doi: 10.1016/j.biopha.2023.115201. Epub 2023 Jul 20.

Abstract

Background: Cardiac arrest (CA), characterized by sudden onset and high mortality rates, is one of the leading causes of death globally, with a survival rate of approximately 6-24%. Studies suggest that the restoration of spontaneous circulation (ROSC) hardly improved the mortality rate and prognosis of patients diagnosed with CA, largely due to ischemia-reperfusion injury.

Main body: Mesenchymal stem cells (MSCs) exhibit self-renewal and strong potential for multilineage differentiation. Their effects are largely mediated by extracellular vesicles (EVs). Exosomes are the most extensively studied subgroup of EVs. EVs mainly mediate intercellular communication by transferring vesicular proteins, lipids, nucleic acids, and other substances to regulate multiple processes, such as cytokine production, cell proliferation, apoptosis, and metabolism. Thus, exosomes exhibit significant potential for therapeutic application in wound repair, tissue reconstruction, inflammatory reaction, and ischemic diseases.

Conclusion: Based on similar pathological mechanisms underlying post-cardiac arrest syndrome involving various tissues and organs in many diseases, the review summarizes the therapeutic effects of MSC-derived exosomes and explores the prospects for their application in the treatment of CA.

Keywords: Cardiac arrest; Exosome; Ischemia-reperfusion injury; Mesenchymal stem cells; Post-cardiac arrest syndrome.

Publication types

  • Review

MeSH terms

  • Exosomes* / metabolism
  • Extracellular Vesicles* / metabolism
  • Heart Arrest* / metabolism
  • Humans
  • Inflammation / metabolism
  • Mesenchymal Stem Cells* / metabolism